title: Prolongation of cardiac ventricular repolarization under paliperidone:  how and how much?
authors.forename: David W
authors.initials: DW
authors.lastname: Hough
authors.forename: Srihari
authors.initials: S
authors.lastname: Gopal
authors.forename: Danielle
authors.initials: D
authors.lastname: Coppola
authors.forename: Bart M
authors.initials: BM
authors.lastname: Remmerie
authors.forename: Joris
authors.initials: J
authors.lastname: Berwaerts
authors.forename: Isaac F
authors.initials: IF
authors.lastname: Nuamah
authors.forename: Patrick C M
authors.initials: PC
authors.lastname: Sterkens
authors.forename: Yimei
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects*; D008133:Long QT Syndrome / Q000139:chemically induced*; D000068882:Paliperidone Palmitate; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents; D051638:Ether-A-Go-Go Potassium Channels; D007555:Isoxazoles; D011743:Pyrimidines; D000068882:Paliperidone Palmitate